Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
Medtronic
Dow
Merck

Last Updated: September 30, 2022

RESCRIPTOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Rescriptor, and when can generic versions of Rescriptor launch?

Rescriptor is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in RESCRIPTOR is delavirdine mesylate. Additional details are available on the delavirdine mesylate profile page.

Drug patent expirations by year for RESCRIPTOR
Drug Prices for RESCRIPTOR

See drug prices for RESCRIPTOR

Recent Clinical Trials for RESCRIPTOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Mental Health (NIMH)Phase 2/Phase 3
University of California, San DiegoPhase 2/Phase 3
National Institutes of Health (NIH)Phase 2/Phase 3

See all RESCRIPTOR clinical trials

US Patents and Regulatory Information for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RESCRIPTOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-002 Jul 14, 1999 See Plans and Pricing See Plans and Pricing
Viiv Hlthcare RESCRIPTOR delavirdine mesylate TABLET;ORAL 020705-001 Apr 4, 1997 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RESCRIPTOR

See the table below for patents covering RESCRIPTOR around the world.

Country Patent Number Title Estimated Expiration
Australia 4213499 See Plans and Pricing
Spain 2093090 See Plans and Pricing
Hungary 9202131 See Plans and Pricing
Denmark 0507861 See Plans and Pricing
European Patent Office 0507861 COMPOSES ANTI-SIDA DIAROMATIQUES SUBSTITUES (DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS) See Plans and Pricing
Russian Federation 2099335 DIAROMATIC COMPOUNDS See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Baxter
Johnson and Johnson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.